4//SEC Filing
Aberman Zami 4
Accession 0001213900-22-007471
CIK 0001158780other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 4:00 PM ET
Size
6.1 KB
Accession
0001213900-22-007471
Insider Transaction Report
Form 4
Aberman Zami
DirectorCEO & Co. Chairman
Transactions
- Purchase
Common Stock
2022-02-10$1.80/sh+80,616$145,109→ 91,756 total(indirect: By Rose Hitech Ltd.)
Holdings
- 1,493,973
Common Stock
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the Tel Aviv Stock Exchange in New Israeli Shekels (NIS), at per share purchase prices ranging from NIS 5.70 to NIS 5.90, inclusive, or ranging from $1.77 to $1.82 in U.S. Dollars, inclusive (based on an exchange rate of NIS 3.221 per U.S. dollar). The Reporting Person undertakes to provide to Pluristem Therapeutics Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
Documents
Issuer
PLURISTEM THERAPEUTICS INC
CIK 0001158780
Entity typeother
Related Parties
1- filerCIK 0001344740
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 4:00 PM ET
- Size
- 6.1 KB